MH
Highly rated in
11
conditions

Dr. Michael R. Harrison

Duke Cancer Center
Durham, NC
Highly rated in
11
conditions
Specialties:Oncology | Hematology Oncology | Hematology
Experience:19 Years
Clinical Trials:Currently Recruiting for 1 Trial
Accepts:New PatientsMedicare
Highly rated in
11
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Michael R. Harrison's experience treating your condition:
About Dr. Michael R. Harrison

Michael Harrison is an Oncologist and a Hematologist Oncology expert in Durham, North Carolina. Harrison has been practicing medicine for over 19 years and is highly rated in 11 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Chromophobe Renal Cell Carcinoma, Endoscopy, and Orchiectomy. He is licensed to treat patients in Wisconsin and North Carolina. Harrison is currently accepting new patients.

His clinical research consists of co-authoring 99 peer reviewed articles and participating in 9 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Michael R. Harrison it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Michael R. Harrison accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
  •  Cigna
  •  Aetna
Call to see if your plan is accepted.
Locations
20 Duke Medicine Cir, Durham, NC 27710
Background & Education
Graduate Institution
Tulane University School Of Medicine, 2004
Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in WI
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma (ODYSSEY RCC)
Enrollment Status: Recruiting
Publish Date: October 14, 2022
A Phase II, Open-Label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC)
Enrollment Status: Terminated
Publish Date: June 29, 2022
Intervention Type: Procedure, Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
Evaluation of the Impact of A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Patients With Prostate Cancer Undergoing Curative-Intent Radiotherapy With Concurrent Androgen Deprivation Therapy (ADT)
Enrollment Status: Completed
Publish Date: July 29, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
Enrollment Status: Completed
Publish Date: December 24, 2020
Intervention Type: Drug
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
Enrollment Status: Completed
Publish Date: December 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
Enrollment Status: Terminated
Publish Date: December 18, 2019
Intervention Type: Behavioral
Study Phase: Not Applicable
EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer
Enrollment Status: Completed
Publish Date: April 18, 2019
Intervention Type: Drug, Behavioral
Study Phase: Phase 2
RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
Enrollment Status: Terminated
Publish Date: December 20, 2018
Intervention Type: Device
Study Phase: Not Applicable
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: December 12, 2017
View 8 Less Clinical Trials -
99 Total Publications
The Rearing of Maternal-Fetal Surgery: The Maturation of a Field from Conception to Adulthood.
Journal: Clinics in perinatology
Published: November 03, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
JZ
Dr. Joshua F. Zeidner
Hematology Oncology | Hematology | Oncology
Highly rated in
15
conditions
Hematology Oncology
Hematology
Oncology

UNC Health

UNC Hospitals Adult Oncology Clinics

101 Manning Dr, 
Chapel Hill, NC 
 9.4 mi

Joshua Zeidner is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Zeidner has been practicing medicine for over 15 years and is highly rated in 15 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in North Carolina. Zeidner is currently accepting new patients.

NK
Dr. Nigel S. Key
Hematology | Hematology Oncology
Highly rated in
35
conditions
Hematology
Hematology Oncology

UNC Health

UNC Health

101 Manning Dr, 
Chapel Hill, NC 
 9.4 mi

Nigel Key is a Hematologist and a Hematologist Oncology expert in Chapel Hill, North Carolina. Key has been practicing medicine for over 42 years and is highly rated in 35 conditions, according to our data. His top areas of expertise are Hemophilia A, Hemophilia B, Blood Clots, Bone Marrow Transplant, and Knee Replacement. He is licensed to treat patients in North Carolina. Key is currently accepting new patients.

TS
Dr. Thomas E. Stinchcombe
Oncology | Hematology Oncology
Highly rated in
13
conditions
Oncology
Hematology Oncology

Duke Health

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 

Thomas Stinchcombe is an Oncologist and a Hematologist Oncology expert in Durham, North Carolina. Stinchcombe has been practicing medicine for over 28 years and is highly rated in 13 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. He is licensed to treat patients in North Carolina. Stinchcombe is currently accepting new patients.